Phthalate Exposures, DNA Methylation and Adiposity in Mexican Children Through Adolescence

Alison Bowman 1, Karen E. Peterson 2,3,4, Dana C. Dolinoy 2,3,4, John D. Meeker 4, Brisa N. Sánchez 5, Adriana Mercado-Garcia 6, Martha M. Téllez-Rojo 6 and Jaclyn M. Goodrich 4

1 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, United States, 2 Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, MI, United States, 3 Center for Human Growth and Development, University of Michigan, Ann Arbor, MI, United States, 4 Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, United States, 5 Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, PA, United States, 6 Center for Research on Nutrition and Health, National Institute of Public Health, Cuernavaca, Mexico

Phthalates are a class of endocrine disrupting chemicals with near ubiquitous exposure to populations around the world. Phthalates have been associated with children’s adiposity in previous studies, though discrepancies exist across studies that may be due to timing of exposure or outcome assessment and population differences (i.e., genetics, other confounders). DNA methylation, an epigenetic modification involved in gene regulation, may mediate the effects of early life phthalate exposures on health outcomes. This study aims to evaluate the mediating effect of DNA methylation at growth-related genes on the association between phthalate exposure and repeat measures of adiposity in Mexican children. Urinary phthalate metabolite concentrations were quantified in mothers at each of the three trimesters of pregnancy and in children at the first peri-adolescent study visit. Blood leukocyte DNA methylation at H19 and HSD11B2 was quantified during the first peri-adolescent visit, and adiposity was measured at the first visit and again ∼3 years later among participants (n = 109 boys, 114 girls) from the Early Life Exposure in Mexico to Environmental Toxicants (ELEMENT) project. Associations between phthalates or DNA methylation and repeat outcome measures were assessed separately in boys and girls using generalized estimating equation models including covariates (urinary specific gravity, maternal education, and child’s age). Sobel tests were used to assess DNA methylation as a mediator in models adjusting for the same covariates. Associations between phthalates and adiposity varied by phthalate and timing of exposure. Early gestation MBP, MIBP, and MBzP were associated with adiposity among girls. For example, among girls first trimester maternal urine concentrations of MIBP were associated with increases in skinfold thickness, BMI-for-age, and waist circumference (p < 0.01). Second trimester and adolescent MBzP were associated with adiposity among boys in opposite directions. In girls, H19 methylation was positively associated with skinfold thickness. No significant mediation of phthalate exposure on
adiposity by DNA methylation of H19 or HSD11B2 was observed (Sobel p > 0.05). However, the mediation analysis was underpowered to detect small to medium effect sizes, and the role of DNA methylation as a mediator between phthalates and outcomes merits further study.

Keywords: DNA methylation, epigenetics, environmental exposures, endocrine disrupting chemicals, children, adolescents, anthropometry

INTRODUCTION

Endocrine disrupting chemicals (EDCs) represent a class of ubiquitous exposures to humans that disrupt the body's natural hormonal functions and subsequent reproductive and developmental health. Phthalates are a class of EDCs that are used as industrial plasticizers and additives in a wide range of consumer products (1). Phthalates can migrate from the products they are added to into the surrounding environment, which may be food, water, or air that has contacted phthalate-containing plastics (1). Humans can then be exposed to phthalates via ingestion, inhalation, absorption or injection, resulting in high detection frequency of phthalate metabolites in human populations. For example, phthalate metabolites were detected at rates of 79.1–99.3% in a study of U.S. children from California (2) and 95.6–100% among pregnant women from Mexico City (3).

Pregnant women and developing children are particularly susceptible to the endocrine disrupting effects of phthalates and other EDCs (1). Phthalate exposures in utero and during childhood have been shown to have lasting health effects including aggressive behavior, learning problems, asthma, allergic symptoms, changes in pubertal timing, and anthropometry (1, 4–6). An effect of particular concern related to phthalate exposure is increased childhood weight status and adiposity. Childhood obesity is highly prevalent in developed nations and has significant potential health implications later in life (7). Previous studies have shown that phthalate exposures, both in utero and during adolescence, are associated with measures of weight status and adiposity, with effects varying by phthalate metabolite, timing of exposure and outcome assessment, and sex (6, 8–12).

While mechanisms underlying the various health effects associated with phthalate exposures are not entirely understood, potential mediating pathways include oxidative stress and disruption of metabolic function (13–15). Epigenetic perturbations including DNA methylation are also emerging as potential mechanisms of phthalates' lasting effects (16, 17). The epigenome consists of heritable (mitotically and in some cases meiotically) alterations to the genome that do not affect the genetic sequence but govern the response of cells, tissues, and individuals to their environment (18, 19). There is growing evidence that environmentally-induced epigenetic perturbations, especially during susceptible periods of development such as gestation, can persist throughout life. Exposure to phthalates both in utero and in childhood has been associated with DNA methylation at specific genes, including imprinted genes such as H19, and repetitive elements (20–22). For example, phthalate exposures both in utero and later in development have been shown to correlate with DNA methylation of H19 and HSD11B2 in peri-adolescent children (20). H19 and HSD11B2 are environmentally responsive genes that serve important roles in regulating growth throughout development. The imprinted H19 gene is involved in growth and adiposity regulation, especially during development (23). DNA methylation status at this gene measured in 17 year old boys and girls has been associated with greater subcutaneous fat measures (23). Additionally, the HSD11B2 gene protects cells from the growth-inhibiting and/or pro-apoptotic effects of cortisol, especially during embryonic development (24). HSD11B2 methylation in placental DNA has been inversely associated with fetal growth (24, 25).

Our prior research in the Early Life Exposure in Mexico to Environmental Toxicants (ELEMENT) project identified associations between phthalate exposure and DNA methylation of H19 and HSD11B2 (20) as well as between phthalate exposure and weight status and adiposity at one childhood time point (10, 11). This study aims to extend the evaluation of phthalate exposures and peri-adolescent adiposity to include trimester-specific measures across pregnancy and repeat measures of adiposity in ELEMENT children. Furthermore, we will test whether DNA methylation at H19 and HSD11B2 are mediators between phthalate exposures during sensitive developmental periods and measures of peri-adolescent adiposity (BMI-for-age z-score, skinfolds thicknesses, and waist circumference).

MATERIALS AND METHODS

Study Participants

The study population consists of participants from the second and third cohorts of the ELEMENT longitudinal study. Initially, mothers were enrolled during the first trimester of pregnancy or at delivery at maternity hospitals in Mexico City. Mothers recruited in their first trimester (T1) attended follow up visits during their second (T2) and third (T3) trimesters with urine and blood collected at each visit. Children of enrolled mothers attended multiple follow up visits from birth until 5 years of age (n = 1,079), with a subset of enrollees returning for additional study visits. At these visits, demographic and dietary data were collected by questionnaire, anthropometric measures were taken, and biospecimens were collected. Complete study methods including exclusion criteria are described elsewhere (26, 27).

This study consists of 250 children who were re-enrolled to attend additional study visits in 2011 and 2012 between the ages of 8 and 14 years during peri-adolescence (referred to here as PA Visit 1), of which 223 children returned between 1.7 and...
4.9 (average = 3.4) years later for additional follow-up between the ages of 9 and 17 years (PA Visit 2). Only children attending both study visits are included here. These children were re-recruited from ELEMENT cohorts 2 and 3, prioritizing families with maternal samples from pregnancy available. Blood and urine were collected from the children at both follow up visits.

Mothers received detailed information of study procedures and signed a letter of informed consent at initial recruitment and at follow up in accordance with the Declaration of Helsinki. Children provided assent in written or verbal forms when age-appropriate for follow-up visits. Research protocols were approved by the Ethics and Research Committees of participating institutions in Mexico and the USA including at the University of Michigan.

Phthalate Metabolite Measurements
Spot urine samples taken at the second morning void were collected from each mother during T1, T2, and T3 as well as from each child at PA visit 1, and stored at −80°C until analysis. Samples were analyzed for nine phthalate metabolites using isotope dilution-liquid chromatography-tandem mass spectrometry (ID LC-MS/MS) according to a modified version of the Centers for Disease Control and Prevention (CDC) method number 6301.01 as described in detail elsewhere (15, 28). The nine phthalate metabolites measured were monoethyl phthalate (MEP), mono-n-buty phthalate (MBP), mono-isobutyl phthalate (MiBP), mono(3-carboxypropyl) phthalate (MCPP), monobenzyl phthalate (MBzP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOH), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP). Urinary specific gravity was measured for each sample using a handheld digital refractometer (ATAGO Company Ltd., Tokyo, Japan). Urinary concentrations below the limit of quantitation (LOQ) were assigned a value of LOQ/sqrt (2).

We calculated the molar sum of individual diethylhexyl phthalate (DEHP) metabolites by summing the quotient of metabolite concentrations by their molecular weights (MW) in grams per mole. DEHP molar sum included MEHP (MW 278), MEHHP (MW 294), MEOHP (MW 292), and MECPP (MW 308). The molar sum was then converted to a concentration in μg/L by multiplying by the MW of DEHP.

DNA Collection, Extraction, and Methylation Analyses
Whole blood samples were collected in PAXgene tubes during the PA Visit 1. DNA was isolated from blood leukocytes using the PAXgene Blood DNA kit (PreAnalytiX, Switzerland). Epitect (Qiagen, Valencia, CA) or EZ DNA Methylation kits (Zymo Research, Irvine, CA) were used according to standard methods to bisulfite convert 0.5–1 μg of genomic DNA, leaving methylated cytosine unchanged and converting unmethylated cytosine to uracil.

The percentage of cells from each sample with methylated DNA was quantified at the H19 paternally imprinted, maternally expressed non-coding RNA transcript and hydroxysteroid (11-beta) dehydrogenase 2, HSD11B2. DNA methylation was measured using pyrosequencing (at 4 CpG sites for H19 and 5 CpG sites for HSD11B2). Additional details on methods including primer sequences and quality control are published elsewhere (20). HSD11B2 and H19 data exhibited batch effects and as such were standardized to controls included on experimental plates as previously described (20). The value of 0% methylation controls on each plate of samples amplified and sequenced together (one laboratory batch) for HSD11B2 was subtracted from the raw DNA methylation values generated for each sample in the same batch, resulting in negative values in some instances.

Anthropometric Measurements
Children's anthropometry was measured at PA Visits 1 and 2. Waist circumference was measured in duplicate to the nearest 0.1 cm with a non-stretchable tape (QM2000; QuickMedical). Tricep and subscapular skinfold thickness were measured in duplicate to the nearest 0.1 mm with a Lange skinfold caliper (Lange; Beta Technology). Child height was measured in duplicate to the nearest 0.1 cm and weight was measured once. For all outcomes measured in duplicate, if intra-personal variability exceeded the measurement tolerance of +/- 0.5 cm for waist circumference and height or 2.0 mm for skinfold thickness, an additional measurement was taken. Observed values were averaged. To serve as a measure of adiposity, tricep and subscapular skinfold thickness were summed. Additionally, age- and sex-specific BMI z-scores were calculated using the 2007 World Health Organization (WHO) reference growth standard (29).

Covariates
The number of years of education completed by the mother at enrollment was used as a measure of socioeconomic status. Children's pubertal status was assessed at PA Visits 1 and 2. Pubic hair staging as well as physician observed breast (females only) and genital (males only) development were assessed according to Tanner Staging methodology as we have previously described for this study (10, 15). Initiation of puberty was defined for girls as a pubic hair stage score or breast development stage score >1 and for boys as a pubic hair stage score or genital development stage score >1.

Statistical Analysis
Data analysis was performed in SAS version 9.4 (SAS Institute, Cary, NC, USA). Individual phthalate metabolite concentrations and molar sum derivatives were natural-log transformed to achieve a normal distribution. All analyses were sex-stratified because phthalate metabolites were previously shown to have sex-specific effects on children's adiposity and on DNA methylation (10, 11, 20). Means, standard deviation (SD), and distributions of phthalate metabolites (geometric means), DNA methylation data, anthropometric outcomes, and maternal education were calculated. To assess whether distributions varied significantly between sexes, Wilcoxon t-tests were used for continuous variables and chi-square tests used performed for dichotomous variables.
A series of generalized estimating equation models were run to assess the direct associations between phthalate exposures as well as DNA methylation on adiposity. Separate models were run for phthalate metabolites at each time point (T1, T2, T3, PA visit 1) as well as each DNA methylation measure as the exposure with each measure of adiposity (waist circumference, skinfold sum, BMI z-score) as a repeated measure outcome from PA visits 1 and 2. Crude models were run adjusted only for urinary specific gravity at time of urine collection for phthalate metabolites and unadjusted for models of DNA methylation. Adjusted models included specific gravity (for phthalate metabolites), age, and maternal education, with age as a repeated measure for visits 1 and 2. For models with BMI-for-age z-score as the outcome, study visit was included instead of age as a repeated measured. Pubertal status was not included in the final models to avoid potential collider bias since prenatal phthalate exposures have been associated with pubertal timing (30, 31).

Triads of exposure (phthalate metabolite), DNA methylation, and outcome were selected for mediation analysis among boys or girls if both the phthalate and locus-specific DNA methylation were significantly associated with at least one measure of adiposity in a given sex (p < 0.1). An alpha value of 10% was used for the selection of variables for mediation analysis so as not to exclude potential associations of interest; an alpha value of 5% was considered statistically significant for all other analyses. Mediation analysis was then performed for each phthalate at each time point with adiposity outcomes and the selected locus. Based on these criteria, MBzP, MIBP, MEHP, and MBzP with DNA methylation of H19 CpG sites 1 and 4 were selected for mediation analysis among girls; MBzP and MEHP and DNA methylation of HSD11B2 CpG sites 1 and 2 were selected for mediation analysis among boys. Models used in mediation analyses are as follows, with X = exposure (phthalate metabolite), M = mediator (locus-specific DNA methylation), Y = outcome (adiposity measure), γ = intercept, and ε = error:

\[ M = \gamma_1 + \alpha X_i + \varepsilon_1 \]
\[ Y = \gamma_2 + \beta_{total} X_i + \varepsilon_2 \]
\[ Y = \gamma_3 + \beta_{direct} X_i + \beta_{mediator} M_i + \varepsilon_3 \]

In mediation analyses, total effect was defined as the effect of the exposure on the outcome unadjusted by the mediator (\( \beta_{total} \)), the direct effect was defined as the effect of the exposure on the outcome adjusted for the mediator (\( \beta_{direct} \)), and the indirect effect was defined as the product of the effect of the exposure on the mediator and the effect of the mediator on the outcome (\( \alpha \times \beta_{mediator} \)). The statistical significance of a non-zero mediation pathway through the indirect effect was measured using a Sobel test with the formula \( \frac{t = \alpha \beta_{mediator} \sigma_{\text{total}}^2 - \alpha \beta_{direct} \sigma_{\text{direct}}^2}{\sigma_{\text{total}}^2} \), where \( \sigma_{\text{total}}^2 \) is the variance of \( \alpha \) and \( \sigma_{\text{direct}}^2 \) is the variance of \( \beta_{direct} \).

Generalized estimating equations were used for mediation analysis of single exposures (phthalate concentration at a single time point), mediators (DNA methylation at a single locus at PA visit 1) and outcomes as repeated measures (skinfold thickness, BMI-for-age z-score, or waist circumference). Mediation analysis models were adjusted for urinary specific gravity, maternal education, and age.

### TABLE 1 | Characteristics of children at two study visits in peri-adolescence.

|                      | Male                          | Female                         | P-valuea |
|----------------------|-------------------------------|--------------------------------|----------|
|                      | n Mean or % SD Min Max        | n Mean or % SD Min Max         |          |
| **PA VISIT 1**       |                               |                                |          |
| Age (years)          | 109 10.3 1.6 8.1 14.4         | 114 10.2 1.7 8.1 14.4          | 0.34     |
| Waist circumference (cm) | 109 69.4 9.7 50.1 95.6      | 114 70.7 10.2 50.5 101.0       | 0.39     |
| Skinfold thickness sum (mm) | 109 25.0 10.7 9.0 64.0     | 114 29.8 11.3 11.5 56.5        | 0.001    |
| BMI-for-age z-score  | 109 0.9 1.2 −2.9 4.0         | 114 0.8 1.3 −2.3 3.7           | 0.61     |
| Puberty initiation   | Yes 52 49.1                   | 37 32.5                        | 0.01b    |
|                      | No 54 50.9                    | 77 67.5                        |          |
| **PA VISIT 2**       |                               |                                |          |
| Age (years)          | 109 13.7 1.8 9.9 17.7         | 114 13.5 1.8 11.0 17.5         | 0.52     |
| BMI-for-age z-score  | 108 0.4 1.3 −3.8 3.4          | 114 0.6 1.2 −2.2 3.2           | 0.22     |
| Waist circumference (cm) | 109 76.4 10.7 59.9 116.5     | 114 79.6 10.3 58.5 109.2       | 0.02     |
| Skinfold thickness sum (mm) | 109 29.3 14.2 10.5 80       | 113 39.9 13.9 15.5 78.5        | <0.0001  |
| Puberty initiation   | Yes 98 92.5                   | 107 95.5                       | 0.34b    |
|                      | No 8 7.5                      | 5 4.5                          |          |
| Maternal education (years) | 109 11.2 2.7 3 20            | 114 10.9 2.8 2 21              | 0.25     |

aT-test for significant difference between boys and girls unless otherwise indicated. Bold values indicates p < 0.05.  
bChi-square test for significant difference between boys and girls.
### TABLE 2 | Blood leukocyte DNA methylation (% of methylated cells) at H19 and HSD11B2 at the first peri-adolescent study visit and phthalate metabolite concentrations in urine (µg/L) at multiple time points.

|                | Males | Females |
|----------------|-------|---------|
| **Males**      |       |         |
| n (Geo) Mean   |       |         |
| (Geo) SD       |       |         |
| n (Geo) Mean   |       |         |
| (Geo) SD       |       |         |
| H19 Methylation|       |         |
| CpG site 1     | 107   | 58.34   | 7.64 |
| CpG site 2     | 107   | 58.35   | 3.37 |
| CpG site 3     | 107   | 59.12   | 3.59 |
| CpG site 4     | 107   | 55.64   | 7.90 |
| HSD11B2 Methylation |     |         |
| CpG site 1     | 107   | −1.48   | 2.37 |
| CpG site 2     | 107   | −0.02   | 0.93 |
| CpG site 3     | 107   | −2.17   | 2.37 |
| CpG site 4     | 107   | −0.71   | 1.60 |
| CpG site 5     | 100   | 0.25    | 4.23 |
| MEP T1         | 85    | 121.94  | 3.99 |
| T2             | 83    | 118.05  | 3.69 |
| T3             | 100   | 114.34  | 3.77 |
| PA visit 1     | 104   | 65.93   | 3.50 |
| MBP T1         | 85    | 54.75   | 4.15 |
| T2             | 83    | 40.18   | 3.74 |
| T3             | 100   | 53.10   | 3.04 |
| PA visit 1     | 104   | 95.07   | 2.36 |
| MCP T1         | 85    | 0.88    | 4.09 |
| T2             | 83    | 0.69    | 4.10 |
| T3             | 100   | 1.81    | 2.74 |
| PA visit 1     | 104   | 9.37    | 2.20 |
| MBzP T1        | 85    | 2.55    | 4.12 |
| T2             | 83    | 2.46    | 3.75 |
| T3             | 100   | 4.43    | 2.56 |
| PA visit 1     | 104   | 5.48    | 2.26 |
| MECPP T1       | 85    | 27.68   | 2.88 |
| T2             | 83    | 28.33   | 2.43 |
| T3             | 100   | 33.04   | 2.50 |
| PA visit 1     | 104   | 65.64   | 2.56 |
| MEHHP T1       | 85    | 14.98   | 3.33 |
| T2             | 83    | 14.95   | 3.03 |
| T3             | 100   | 19.85   | 2.88 |
| PA visit 1     | 104   | 47.94   | 2.68 |

(Continued)
TABLE 3 | Associations between blood leukocyte DNA methylation and measures of adiposity from a generalized estimating equation relating repeated measures of adiposity outcomes stratified by sex.

| Skinfold thickness (mm) | BMI-for-age z-score | Waist circumference (cm) |
|-------------------------|---------------------|-------------------------|
|                         | Crude model\(^a\)  | Adjusted model          | Crude model\(^a\)  | Adjusted model          | Crude model\(^a\)  | Adjusted model          |
| **FEMALES**             |                     |                         |                     |                         |                     |                         |
| DNA methylation at H19  |                     |                         |                     |                         |                     |                         |
| CpG site 1              | 0.15 (−0.11, 0.41)  | 0.35 (0.07, 0.62)**     | 0.02 (−0.01, 0.05)  | 0.02 (−0.01, 0.05)      | −0.02 (−0.24, 0.2)  | 0.16 (−0.07, 0.39)      |
| CpG site 2              | 0.07 (−0.19, 0.33)  | 0.07 (−0.24, 0.39)      | 0 (−0.03, 0.02)     | 0 (−0.03, 0.02)         | 0.06 (−0.12, 0.24)  | 0.06 (−0.16, 0.28)      |
| CpG site 3              | 0.17 (−0.43, 0.76)  | 0.32 (−0.3, 0.93)       | 0.01 (−0.05, 0.06)  | 0.01 (−0.05, 0.06)      | 0.01 (−0.46, 0.47)  | 0.14 (−0.33, 0.62)      |
| CpG site 4              | 0.18 (−0.07, 0.42)  | 0.36 (0.1, 0.62)***     | 0.02 (0, 0.05)      | 0.02 (0, 0.05)*         | 0.03 (−0.17, 0.23)  | 0.2 (−0.02, 0.41)*      |
| **MALES**               |                     |                         |                     |                         |                     |                         |
| DNA methylation at H19  |                     |                         |                     |                         |                     |                         |
| CpG site 1              | −0.32 (−1.54, 0.9)  | −0.62 (−1.9, 0.67)      | −0.04 (−0.17, 0.1)  | −0.04 (−0.18, 0.1)      | −0.05 (−1.15, 1.05) | −0.34 (−1.46, 0.79)     |
| CpG site 2              | 0.7 (−1.8, 3.21)    | 1.68 (−0.96, 4.32)      | 0.18 (−0.07, 0.42)  | 0.18 (−0.07, 0.42)      | 0.32 (−1.76, 2.4)   | 1.23 (−0.92, 3.37)      |
| CpG site 3              | 0.08 (−0.89, 1.05)  | −0.06 (−1.13, 1)        | 0.01 (−0.1, 0.12)   | 0.01 (−0.1, 0.12)       | 0.26 (−0.64, 1.17)  | 0.13 (−0.85, 1.1)       |
| CpG site 4              | 0 (−1.15, 1.14)     | 0.3 (−0.84, 1.45)       | 0.07 (−0.03, 0.18)  | 0.07 (−0.03, 0.18)      | 0.35 (−0.74, 1.43)  | 0.63 (−0.43, 1.69)      |
| CpG site 5              | −0.04 (−0.55, 0.47) | −0.19 (−0.74, 0.35)     | −0.01 (−0.06, 0.04) | −0.01 (−0.06, 0.04)     | 0 (−0.39, 0.4)      | −0.14 (−0.56, 0.28)     |
| CpG site 6              | 0.19 (−0.04, 0.40)  | 0.19 (−0.04, 0.40)      | 0.19 (−0.04, 0.40)  | 0.19 (−0.04, 0.40)      | 0.19 (−0.04, 0.40)  | 0.19 (−0.04, 0.40)      |

\(^a\)Crude models are unadjusted and adjusted models include maternal education and age. Effect estimate (95% confidence intervals) are displayed.

\(p < 0.10\), **\(p < 0.05\), ***\(p < 0.01\).
TABLE 4 | Associations between natural log–transformed phthalate concentrations (μg/L) and measures of adiposity from a generalized estimating equation relating repeated measures of adiposity outcomes among females.

|                  | Skinfold thickness (mm) | BMI–for–age z-score | Waist circumference (cm) |
|------------------|-------------------------|----------------------|--------------------------|
|                  | Crude model²            | Adjusted model       | Crude model²            | Adjusted model       |
| MEP              |                         |                      |                          |                       |
| T1               | 0.80 (−0.82, 2.42)      | 1.27 (−0.52, 3.06)   | 0.06 (−0.12, 0.23)      | 0.06 (−0.12, 0.24)   |
| T2               | 0.69 (−1.64, 3.02)      | 0.54 (−1.82, 2.90)   | 0.00 (−0.21, 0.22)      | 0.02 (−0.20, 0.25)   |
| T3               | 1.16 (−0.79, 3.12)      | 1.24 (−0.93, 3.42)   | 0.01 (−0.21, 0.23)      | 0.01 (−0.21, 0.23)   |
| PA visit 1       | 0.49 (−1.01, 1.99)      | 0.13 (−1.45, 1.72)   | 0.05 (−0.1, 0.20)       | 0.05 (−0.10, 0.20)   |
| MBP              |                         |                      |                          |                       |
| T1               | 1.20 (−0.79, 3.18)      | 1.88 (−0.42, 4.18)   | 0.24 (0.03, 0.46)**     | 0.25 (0.03, 0.46)**  |
| T2               | −1.13 (−3.44, 1.19)     | −1.45 (−3.67, 0.77)  | −0.12 (−0.32, 0.08)     | −0.12 (−0.32, 0.08)  |
| T3               | 0.23 (−1.99, 2.45)      | 0.05 (−2.23, 2.32)   | −0.06 (−0.25, 0.14)     | −0.06 (−0.26, 0.14)  |
| PA visit 1       | −1.54 (−3.90, 0.82)     | −2.28 (−4.86, 0.29)* | −0.21 (−0.46, 0.03)*    | −0.21 (−0.46, 0.03)* |
| MCPP             |                         |                      |                          |                       |
| T1               | 0.30 (−1.93, 2.53)      | 0.97 (−1.64, 3.58)   | 0.18 (−0.08, 0.44)      | 0.18 (−0.08, 0.45)   |
| T2               | −1.59 (−4.55, 1.37)     | −1.49 (−4.36, 1.38)  | −0.16 (−0.42, 0.11)     | −0.15 (−0.40, 0.11)  |
| T3               | −0.96 (−3.74, 1.83)     | −1.08 (−4.03, 1.87)  | −0.11 (−0.36, 0.15)     | −0.11 (−0.36, 0.14)  |
| PA visit 1       | −0.96 (−3.48, 1.55)     | −1.30 (−4.15, 1.54)  | −0.19 (−0.45, 0.07)     | −0.19 (−0.44, 0.07)  |
| MBzP             |                         |                      |                          |                       |
| T1               | −0.51 (−2.38, 1.36)     | −0.10 (−2.21, 2.00)  | 0.04 (−0.17, 0.25)      | 0.04 (−0.18, 0.25)   |
| T2               | −2.31 (−4.56, −0.06)**  | −2.53 (−4.78, −0.28)** | −0.21 (−0.45, 0.03)*   | −0.22 (−0.46, 0.03)* |
| T3               | −0.83 (−3.25, 1.59)     | −1.20 (−3.81, 1.42)  | −0.22 (−0.45, 0.01)*    | −0.23 (−0.46, 0.01)* |
| PA visit 1       | 0.52 (−2.44, 3.48)      | 0.61 (−2.67, 3.88)   | 0.11 (−0.21, 0.42)      | 0.10 (−0.23, 0.43)   |
| MECPP            |                         |                      |                          |                       |
| T1               | −0.09 (−2.93, 2.76)     | 0.68 (−2.35, 3.70)   | 0.13 (−0.16, 0.41)      | 0.13 (−0.16, 0.41)   |
| T2               | −0.84 (−3.84, 2.15)     | −1.24 (−4.61, 2.13)  | −0.06 (−0.40, 0.27)     | −0.08 (−0.42, 0.26)  |
| T3               | −0.04 (−2.87, 2.78)     | −0.72 (−3.63, 2.19)  | −0.01 (−0.25, 0.23)     | −0.02 (−0.26, 0.21)  |
| PA visit 1       | −0.13 (−3.22, 2.96)     | 0.74 (−2.73, 4.21)   | 0.11 (−0.23, 0.45)      | 0.10 (−0.25, 0.45)   |
| MEHHP            |                         |                      |                          |                       |
| T1               | 0.07 (−2.34, 2.47)      | 0.89 (−1.72, 3.49)   | 0.13 (−0.11, 0.38)      | 0.13 (−0.12, 0.38)   |
| T2               | −1.02 (−3.61, 1.57)     | −1.35 (−4.19, 1.49)  | −0.11 (−0.40, 0.19)     | −0.12 (−0.42, 0.17)  |
| T3               | −0.07 (−2.67, 2.53)     | −0.56 (−3.22, 2.10)  | −0.03 (−0.25, 0.19)     | −0.03 (−0.25, 0.19)  |
| PA visit 1       | 0.10 (−2.87, 3.06)      | 1.12 (−2.29, 4.52)   | 0.12 (−0.22, 0.45)      | 0.11 (−0.23, 0.45)   |

(Continued)
TABLE 4 | Continued

|                  | Skinfold thickness (mm) | BMI-for-age z-score | Waist circumference (cm) |
|------------------|-------------------------|---------------------|-------------------------|
|                  | Crude model\(^a\)      | Adjusted model      | Crude model\(^a\)      | Adjusted model      |
| MEHP             |                         |                     |                         |                     |
| T1               | −2.10 (−4.62, 0.42)     | −1.95 (−4.46, 0.56) | −0.13 (−0.37, 0.12)     | −0.13 (−0.38, 0.12) |
| T2               | −1.48 (−4.23, 1.27)     | −2.07 (−4.97, 0.83) | −0.16 (−0.47, 0.14)     | −0.19 (−0.50, 0.13) |
| T3               | −1.09 (−4.20, 2.03)     | −1.35 (−4.39, 1.7)  | −0.11 (−0.36, 0.14)     | −0.11 (−0.36, 0.14) |
| PA visit 1       | −0.96 (−4.12, 2.20)     | −0.77 (−4.14, 2.61) | −0.03 (−0.35, 0.29)     | −0.03 (−0.35, 0.29) |
| MEOHP            |                         |                     |                         |                     |
| T1               | −0.20 (−2.61, 2.20)     | 0.46 (−2.13, 3.06)  | 0.09 (−0.15, 0.34)      | 0.09 (−0.16, 0.34)  |
| T2               | −1.20 (−3.84, 1.43)     | −1.73 (−4.65, 1.19) | −0.13 (−0.44, 0.17)     | −0.15 (−0.45, 0.15) |
| T3               | 0.01 (−2.64, 2.67)      | −0.56 (−3.32, 2.20) | −0.03 (−0.24, 0.18)     | −0.04 (−0.24, 0.17) |
| PA visit 1       | −0.44 (−3.43, 2.54)     | 0.56 (−2.87, 3.99)  | 0.05 (−0.28, 0.38)      | 0.04 (−0.30, 0.39)  |
| ∑DEHP            |                         |                     |                         |                     |
| T1               | −0.66 (−3.45, 2.12)     | 0.06 (−2.82, 2.95)  | 0.08 (−0.20, 0.36)      | 0.08 (−0.20, 0.36)  |
| T2               | −1.02 (−3.99, 1.95)     | −1.44 (−4.77, 1.89) | −0.09 (−0.43, 0.25)     | −0.11 (−0.45, 0.23) |
| T3               | −0.07 (−3.08, 2.94)     | −0.75 (−3.69, 2.39) | −0.02 (−0.27, 0.23)     | −0.03 (−0.28, 0.21) |
| PA visit 1       | −0.07 (−3.18, 3.04)     | 0.87 (−2.65, 4.39)  | 0.11 (−0.23, 0.46)      | 0.10 (−0.25, 0.46)  |

\(^a\)Crude models are adjusted for specific gravity. Adjusted models include specific gravity, maternal education, and age. Effect estimates (95% CI) are displayed.

\(^*p < 0.10, **p < 0.05, ***p < 0.01\)
### TABLE 5 | Associations between natural log-transformed phthalate concentrations (μg/L) and measures of adiposity from a generalized estimating equation relating repeated measures of adiposity outcomes among males.

|                  | Skinfold thickness (mm) | BMI-for-age z-score | Waist circumference (cm) |
|------------------|-------------------------|---------------------|--------------------------|
|                  | Crude model            | Adjusted model      | Crude model            | Adjusted model |
| **MEP**          |                         |                     |                         |                |
| T1               | 0.05 (−1.84, 1.95)      | −0.08 (−1.95, 1.80) | 0.01 (−0.15, 0.18)      | −0.25 (−1.65, 1.15) |
| T2               | −0.10 (−2.79, 2.59)     | −0.30 (−2.99, 2.39) | −0.03 (−0.23, 0.17)     | −0.08 (−1.83, 1.68) |
| T3               | −0.16 (−2.55, 2.22)     | −0.37 (−2.75, 2.01) | −0.06 (−0.24, 0.12)     | −0.21 (−1.84, 1.42) |
| PA visit 1       | −1.11 (−2.78, 0.56)     | −1.30 (−2.97, 0.36) | −0.07 (−0.23, 0.09)     | −0.47 (−1.83, 0.89) |
| **MBP**          |                         |                     |                         |                |
| T1               | 0.33 (−1.38, 2.03)      | 0.46 (−1.38, 2.31)  | 0.04 (−0.15, 0.23)      | 0.03 (−1.4, 1.46) |
| T2               | −0.89 (−3.61, 1.83)     | −1.24 (−4.14, 1.66) | 0.00 (−0.27, 0.27)      | −0.10 (−2.07, 1.87) |
| T3               | 0.03 (−2.25, 2.30)      | −0.10 (−2.63, 2.42) | 0.02 (−0.21, 0.24)      | 0.18 (−1.52, 1.89) |
| PA visit 1       | 0.50 (−2.38, 3.38)      | 0.86 (−2.1, 3.82)   | 0.03 (−0.25, 0.31)      | −0.39 (−2.51, 1.73) |
| **MBzP**         |                         |                     |                         |                |
| T1               | −0.29 (−2.10, 1.52)     | 0.27 (−1.53, 2.08)  | 0.02 (−0.16, 0.21)      | −0.53 (−2.00, 0.94) |
| T2               | 0.16 (−2.61, 2.90)      | 0.41 (−2.39, 2.32)  | 0.11 (−0.15, 0.36)      | 0.53 (−1.46, 2.53) |
| T3               | −1.47 (−3.77, 0.84)     | −1.39 (−3.98, 1.19) | −0.07 (−0.29, 0.15)     | −1.03 (−2.89, 0.84) |
| PA visit 1       | 0.25 (−2.74, 3.25)      | −0.11 (−3.12, 2.91) | 0.00 (−0.30, 0.29)      | 0.80 (−1.39, 3.00) |
| **MCPP**         |                         |                     |                         |                |
| T1               | 1.88 (−1.22, 4.98)      | 2.29 (−0.95, 5.53)  | 0.25 (−0.06, 0.57)      | 1.69 (−0.71, 4.10) |
| T2               | 1.26 (−2.19, 4.71)      | 0.90 (−2.68, 4.49)  | 0.12 (−0.21, 0.45)      | 1.44 (−1.16, 4.04) |
| T3               | 0.21 (−2.90, 3.32)      | 0.33 (−3.1, 3.75)   | 0.03 (−0.28, 0.33)      | 0.14 (−2.12, 2.40) |
| PA visit 1       | −2.34 (−5.22, 0.55)     | −1.81 (−4.73, 1.11) | −0.21 (−0.49, 0.07)     | −2.59 (−4.78, −0.41)** |
| **MBzP**         |                         |                     |                         |                |
| T1               | 1.48 (−0.66, 3.61)*     | 1.91 (−0.30, 4.12)* | 0.18 (−0.01, 0.38)*     | 1.13 (−0.49, 2.75) |
| T2               | 2.07 (−0.30, 4.43)*     | 2.00 (−0.43, 4.43)  | 0.25 (0.01, 0.49)**     | 2.28 (0.48, 4.08)** |
| T3               | −0.19 (−2.67, 2.29)     | −0.49 (−2.93, 1.94) | 0.12 (−0.34, 0.09)      | 0.15 (−1.97, 2.27) |
| PA visit 1       | −2.50 (−4.83, −0.19)**  | −2.43 (−4.69, −0.17)** | 0.16 (−0.40, 0.08)     | −1.99 (−3.92, −0.05)** |
| **MECPP**        |                         |                     |                         |                |
| T1               | 2.08 (−0.96, 5.13)      | 2.28 (−0.76, 5.31)  | 0.20 (−0.11, 0.52)      | 1.23 (−1.30, 3.75) |
| T2               | 0.70 (−3.23, 4.62)      | 0.54 (−3.29, 4.37)  | 0.24 (−0.16, 0.65)      | 1.89 (−1.19, 4.96) |
| T3               | −0.13 (−2.84, 2.58)     | −0.07 (−2.75, 2.61) | −0.05 (−0.35, 0.25)     | −0.69 (−3.1, 1.71) |
| PA visit 1       | −0.76 (−2.81, 1.29)     | −0.75 (−2.91, 1.42) | −0.07 (−0.28, 0.14)     | −0.44 (−2.01, 1.13) |

(Continued)
| TABLE 5 | Continued |
|-----------------------------------------------|

**Skinfold thickness (mm)**

| MEHHP | Crude model[^a] | Adjusted model |
|-------|-----------------|----------------|
| T1    | 1.56 (−0.85, 3.98) | 1.88 (−0.56, 4.32) |
| T2    | 0.65 (−2.28, 3.58)  | 0.41 (−2.54, 3.37)  |
| T3    | −0.47 (−2.79, 1.85) | −0.45 (−2.74, 1.83) |
| PA visit 1 | −0.56 (−2.4, 1.29) | −0.55 (−2.49, 1.38) |

| MEHP | Crude model[^a] | Adjusted model |
|------|-----------------|----------------|
| T1    | 2.40 (−0.61, 5.41) | 2.67 (−0.37, 5.71)* |
| T2    | 1.06 (−1.90, 4.02)  | 0.63 (−2.42, 3.67)  |
| T3    | −0.33 (−3.28, 2.62) | −0.63 (−3.63, 2.37) |
| PA visit 1 | −1.40 (−3.32, 0.52) | −1.90 (−3.91, 0.11)* |

| MEOHP | Crude model[^a] | Adjusted model |
|-------|-----------------|----------------|
| T1    | 1.59 (−0.86, 4.03) | 1.88 (−0.58, 4.35) |
| T2    | 0.79 (−2.26, 3.83)  | 0.48 (−2.56, 3.52)  |
| T3    | −0.69 (−3.09, 1.70) | −0.76 (−3.10, 1.58) |
| PA visit 1 | −0.75 (−2.57, 1.08) | −0.75 (−2.68, 1.18) |

| ∑DEHP | Crude model[^a] | Adjusted model |
|-------|-----------------|----------------|
| T1    | 2.28 (−0.95, 5.5)  | 2.58 (−0.66, 5.83)  |
| T2    | 0.82 (−2.64, 4.25)  | 0.56 (−2.87, 4.00)  |
| T3    | −0.43 (−3.15, 2.29) | −0.41 (−3.09, 2.27) |
| PA visit 1 | −0.72 (−2.67, 1.23) | −0.76 (−2.79, 1.28) |

| BMI-for-age z-score | Crude model[^a] | Adjusted model |
|---------------------|-----------------|----------------|
| T1                  | 0.19 (−0.05, 0.43) | 0.20 (−0.04, 0.44) |
| T2                  | 0.18 (−0.12, 0.49)  | 0.19 (−0.12, 0.49)  |
| T3                  | −0.01 (−0.26, 0.25) | 0.01 (−0.25, 0.26) |
| PA visit 1           | −0.05 (−0.24, 0.14) | −0.07 (−0.26, 0.12) |

| Waist circumference (cm) | Crude model[^a] | Adjusted model |
|--------------------------|-----------------|----------------|
| T1                       | 0.97 (−0.98, 2.92) | 1.30 (−0.7, 3.29) |
| T2                       | 1.61 (−0.54, 3.76)  | 1.30 (−0.93, 3.53)  |
| T3                       | −0.59 (−2.58, 1.40) | −0.44 (−2.29, 1.41) |
| PA visit 1               | −0.46 (−1.83, 0.91) | −0.56 (−1.88, 0.76) |

[^a]: Crude models are adjusted for specific gravity. Adjusted models include specific gravity, maternal education, and age. Effect estimates (95% CI) are displayed.

*[^p < 0.10, **[^p < 0.05
| Exposure | Skinfold thickness (mm) | BMI for age z-score | Waist circumference (cm) |
|----------|-------------------------|---------------------|-------------------------|
|          | Total effect            | Direct effect       | Indirect effect (Sobel p-value) | Total effect | Direct effect | Indirect effect (Sobel p-value) | Total effect | Direct effect | Indirect effect (Sobel p-value) |
|          |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| H19 CpG #4 AS MEDIATOR |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| MBP      |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| T1       | 3.41 (1.5, 5.31)**      | 2.9 (0.76, 5.03)**  | 0.28 (0.12, 0.45)**       | 0.25 (0.07, 0.43)** | 0.03 (0.35)       | 2.33 (0.86, 3.8)**       | 2.05 (0.38, 3.73)** | 0.27 (0.3) |                           |
| T2       | 1.96 (1.46, 2.00)       | 0.71 (2.83, 1.41)   | 0.04 (0.18, 0.25)         | 0.0 (0.17, 0.21)  | 0.03 (0.23)       | 0.03 (0.17, 1.76)        | 0.03 (0.26, 1.47)  | 0.3 (0.22) |                           |
| T3       | 3.02 (2.97, 3.08)       | 0.90 (1.6, 2.68)    | 0.06 (0.26, 0.14)         | 0.04 (0.24, 0.16) | 0.01 (0.59)       | 0.03 (0.32)              | 0.04 (0.32, 0.26)  | 0.37 (0.28) |                           |
| PA visit | 1.29 (3.32, 3.41)       | 0.29 (3.29, 0.30)   | 0.01 (0.32, 0.3)          | 0.03 (0.35)      | 0.02 (0.32)       | 0.03 (0.26)              | 0.03 (0.31)      | 0.02 (0.32) |                           |
| MBzP     |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| T1       | 3.67 (4.78, 0.87)**     | 2.72 (4.74, 0.69)** | 0.22 (0.46, 0.03)*        | 0.00 (0.05)      | 0.00 (0.05)       | 2.01 (0.40, 0.05)*        | 2.06 (0.39, 0.18) | 0.04 (0.85) |                           |
| T2       | 1.20 (1.49, 1.51)       | 1.97 (2.65, 0.95)   | 0.18 (0.25, 0.2)          | 0.07 (0.03)      | 0.08 (0.07)       | 0.01 (0.05)              | 0.01 (0.09)      | 0.03 (0.12) |                           |
| T3       | 0.23 (3.39, 0.73)       | 0.40 (0.31, 0.2)    | 0.03 (0.35)               | 0.03 (0.35)      | 0.02 (0.32)       | 0.03 (0.26)              | 0.03 (0.31)      | 0.02 (0.32) |                           |
| PA visit | 1.27 (3.31, 2.49)       | 0.57 (3.32, 2.18)   | 0.03 (0.26)               | 0.03 (0.26)      | 0.03 (0.26)       | 0.03 (0.26)              | 0.03 (0.26)      | 0.03 (0.26) |                           |
| H19 CpG #1 AS MEDIATOR |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| MBP      |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| T1       | 1.88 (0.14, 2.18)       | 1.54 (0.85, 2.93)   | 0.33 (0.22)               | 0.02 (0.37)      | 0.02 (0.37)       | 1.72 (0.09, 3.50)*        | 1.48 (0.39, 3.35) | 0.17 (0.34) |                           |
| T2       | 1.95 (1.46, 2.00)       | 0.71 (2.83, 1.41)   | 0.04 (0.18, 0.25)         | 0.03 (0.23)      | 0.03 (0.23)       | 0.03 (0.23)              | 0.03 (0.26, 1.47) | 0.3 (0.22) |                           |
| T3       | 3.03 (2.97, 3.08)       | 0.90 (1.6, 2.68)    | 0.06 (0.26, 0.14)         | 0.04 (0.24, 0.16) | 0.01 (0.59)       | 0.03 (0.32)              | 0.04 (0.32, 0.26) | 0.37 (0.28) |                           |
| PA visit | 1.29 (3.32, 3.41)       | 0.29 (3.29, 0.30)   | 0.01 (0.32, 0.3)          | 0.03 (0.35)      | 0.02 (0.32)       | 0.03 (0.26)              | 0.03 (0.31)      | 0.02 (0.32) |                           |
| MBzP     |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| T1       | 3.41 (1.5, 5.31)**      | 2.98 (0.84, 5.12)** | 0.28 (0.12, 0.45)**       | 0.26 (0.08, 0.44)** | 0.02 (0.48)       | 2.33 (0.86, 3.8)**       | 2.13 (0.47, 3.79)** | 0.19 (0.42) |                           |
| T2       | 1.46 (0.76, 3.68)       | 0.95 (1.57, 3.48)   | 0.03 (0.19, 0.24)         | 0.01 (0.25, 0.23) | 0.03 (0.31)       | 0.56 (1.61, 2.72)        | 0.39 (2.02, 2.8)  | 0.23 (0.39) |                           |
| T3       | 2.17 (1.32, 5.56)       | 1.85 (1.74, 5.45)   | 0.47 (0.35)               | 0.08 (0.23, 0.3)  | 0.02 (0.41)       | 1.53 (1.14, 4.23)        | 1.53 (1.26, 4.32) | 0.17 (0.43) |                           |
| PA visit | 0.38 (3.32, 2.47)       | 0.23 (3.17, 2.7)    | 0.08 (0.38, 0.22)         | 0.01 (0.66)      | 0.01 (0.66)       | 1.15 (3.29, 0.99)        | 1.13 (3.33, 1.08) | 0.06 (0.67) |                           |
| MBzP     |                         |                     |                           |                 |                 |                           |                 |                 |                           |
| T1       | −0.1 (−2.21, 2.00)      | −0.65 (−2.75, 1.45) | 0.44 (0.18)               | 0.04 (0.18, 0.25) | 0.02 (0.32)       | 0.03 (0.3)              | 0.03 (1.7, 1.76)  | 0.24 (0.28) |                           |
| T2       | −2.53 (4.78, −0.28)**   | −2.73 (4.82, −0.65)** | 0.08 (0.77)               | −0.22 (0.46, 0.03)* | 0.00 (0.77)       | −2.01 (4.07, 0.05)*      | −2.09 (4.06, −0.12)** | 0.04 (0.77) |                           |

(Continued)
TABLE 8 (Continued)

| Exposure | Total effect | Direct effect | Indirect effect (Sobel p-value) |
|----------|-------------|---------------|--------------------------------|
| MEHP     | 1.95 (−3.91, 0.00) | 0.13 (−3.91, 0.00) | 0.06 (−3.91, 0.00) |
| T2       | 2.07 (−1.75, 0.00) | −0.19 (−1.75, 0.00) | 0.00 (−1.75, 0.00) |
| T3       | 1.35 (−0.76, 1.75) | 0.00 (−0.76, 1.75) | 0.00 (−0.76, 1.75) |
| PA       | −0.77 (−0.76, 1.75) | 0.00 (−0.76, 1.75) | 0.00 (−0.76, 1.75) |

Note: Effect estimates (95% CI) are reported in the table. p < 0.05 after adjusting for sex.

Prenatal Phthalate Exposure Biomarkers and Adiposity

We ran crude and adjusted models to assess the total effect of trimester-specific phthalate exposure on adiposity outcomes for females (Table 4) and males (Table 5). Three phthalate metabolites at earlier gestational periods were associated with at least one measure of girls’ adiposity in adjusted models at the 95% confidence level: MBP (T1), MIBP (T1), and MBzP (T2; Table 4). Positive associations were observed between T1 MBP and MIBP, both metabolites of dibutyl phthalate (DBP), and all outcomes (for MBP, p-value = 0.03 and 0.06 for adjusted models of BMI and waist circumference; for MIBP, p = 0.0005, 0.0008, and 0.0019 for skinfold thickness, BMI, and waist circumference). MBzP from T2 and T3 were inversely associated with all three adiposity outcomes among girls, and T2 MBzP was significantly associated with decreased skinfold thickness (p = 0.03). MEHP was also considered for mediation analysis as T1 MEHP was inversely associated with waist circumference (p = 0.08). Among boys, after covariate adjustment T2 MBzP was associated with increased BMI and waist circumference (p = 0.04 and 0.02; Table 5). MEHP was considered in mediation analysis as T1 MEHP was positively associated with skinfold thickness (p = 0.08) and BMI (0.05).

Peri-Adolescent Phthalate Exposure Biomarkers and Adiposity

We examined associations between children’s urinary phthalate concentrations at visit 1 with adiposity measures from visits 1 and 2. Significant associations between childhood phthalates and outcomes were only observed among boys. MBzP was inversely associated with skinfold thickness (p = 0.03) and waist circumference (p = 0.04) among boys in adjusted models.

Mediation Analysis

Results (total, direct, and indirect effect estimates) from mediation analysis are presented in Table 6 for girls and Table 7 for boys; for additional estimates from the mediation models see Supplemental Tables 1, 2. For both boys and girls, the Sobel tests revealed no statistically significant mediation effects for DNA methylation at the selected loci in the association between the phthalates and the outcome measures at the 95% confidence level. The final sample size for analysis in this study was 114 for girls and 109 for boys, although missing data for specific exposures or mediators decreased some model sample sizes further. Table 8 displays minimum sample sizes needed to detect a significant mediation pathway via the Sobel test given specified effect sizes for standardized exposures, standardized mediators, and skinfold thickness as the outcome. Given the required sample sizes, this study has enough observations to detect significant mediation...
**TABLE 7 | Mediation analysis among males.**

| Exposure | Total effect | Direct effect | Indirect effect (Sobel p-value) | Total effect | Direct effect | Indirect effect (Sobel p-value) | Total effect | Direct effect | Indirect effect (Sobel p-value) |
|----------|--------------|---------------|-------------------------------|--------------|---------------|-------------------------------|--------------|---------------|-------------------------------|
| **Skinfold thickness (mm)** | | | | **B MI for age z-s core** | | | | **Waist circumference (cm)** | | | |
| **HSD11B2 CpG #1 AS MEDIATOR** | | | | **HSD11B2 CpG #2 AS MEDIATOR** | | | | |
| MEHP | | | | | | | | | |
| T1 | 2.67 (−0.37, 5.71)* | 3.12 (−0.09, 6.33)* | −0.48 (0.27) | 0.28 (0.002, 0.57)** | 0.31 (0.01, 0.60)** | −0.02 (0.40) | 1.86 (−0.61, 4.33) | 2.25 (−0.3, 4.8)* | −0.39 (0.26) |
| T2 | 0.63 (−2.42, 3.67) | 0.9 (−2.13, 3.93) | −0.24 (0.55) | 0.23 (−0.08, 0.55) | 0.25 (−0.06, 0.56) | −0.01 (0.58) | 1.41 (−0.91, 3.74) | 1.61 (−0.67, 3.9) | −0.19 (0.55) |
| T3 | −0.63 (−3.63, 2.37) | 0.3 (−2.34, 2.94) | −0.89 (0.11) | 0.09 (−0.18, 0.37) | 0.18 (−0.08, 0.43) | −0.06 (0.21) | −0.34 (−2.57, 1.89) | 0.37 (−1.67, 2.41) | −0.68 (0.12) |
| PA visit 1 | −1.90 (−3.91, 0.11)* | −1.87 (−3.76, 0.02)* | −0.24 (0.37) | −0.15 (−0.36, 0.05) | −0.16 (−0.36, 0.04) | −0.01 (0.68) | −1.33 (−2.9, 0.24) | −1.31 (−2.86, 0.23) | −0.11 (0.47) |
| MBzP | | | | | | | | | |
| T1 | 1.91 (−0.3, 4.12)* | 1.71 (−0.41, 3.83) | 0.23 (0.57) | 0.19 (−0.001, 0.39)* | 0.18 (−0.01, 0.38)* | 0.01 (0.59) | 1.55 (−0.13, 3.22)* | 1.38 (−0.22, 2.99)* | 0.19 (0.36) |
| T2 | −0.49 (−2.93, 1.94) | −1.35 (−3.8, 1.1) | 0.84 (0.12) | −0.12 (−0.33, 0.09) | −0.17 (−0.40, 0.07) | 0.05 (0.25) | −0.35 (−2.24, 1.55) | −0.98 (−2.98, 1.02) | 0.63 (0.14) |
| T3 | −2.43 (−4.69, −0.17)** | −2.29 (−4.58, −0.01)* | −0.11 (0.73) | −0.17 (−0.41, 0.07) | −0.17 (−0.42, 0.08) | 0.00 (0.77) | −1.91 (−3.64, −0.19)** | −1.86 (−3.6, −0.11)** | −0.05 (0.73) |

**Effect estimates (95% CI) are reported in the table. *p < 0.1, **p < 0.05.**

Phthalate concentrations (µg/L) were natural log transformed. Total effects represent the effect estimate of the phthalate concentrations on measures of adiposity from a generalized estimating equation relating repeated measures of adiposity to phthalates leaving the potential mediator (DNA methylation at HSD11B2 CpG sites 1 or 2) out of the model and adjusting for specific gravity, maternal education, and age. Direct effects represent the effect estimate of phthalate concentration in the same model but with DNA methylation also included. The indirect effect is the product of the effect of the exposure on the mediator and the effect of the mediator on the outcome. The Sobel test was used to test significance of the mediation pathway.
Discussion

Our results show that phthalate exposures during pregnancy and in early adolescence have sex-specific associations with DNA methylation and sex- and exposure timing-specific associations with repeat measures of adolescent adiposity. Even though the analysis was underpowered to detect mediation pathways with small to medium effect sizes, there was suggestive evidence for DNA methylation as a mediator between phthalate exposure and adiposity (Sobel $p > 0.05$). For example among girls, the positive associations between T1 or T2 MiBP and adiposity may be explained in part by the indirect effect of increased $H19$ methylation. On the other hand, accounting for DNA methylation may reveal stronger direct relationships between exposures and outcomes in cases when epigenetic change may be protecting against the effects of exposure. Among girls, controlling for $H19$ methylation revealed a stronger inverse association between T3 MBzP and skinfold thickness (Figure 1) or BMI-for-age (Table 6). This highlights the importance of considering epigenetics as a mediator not only in the traditional sense but also as a biological buffer that may influence susceptibility to effects from toxicant exposures.

This study expands upon previous ELEMENT research reporting associations between phthalates from T3 and PA visit 1 with adiposity at PA visit 1 (10) to include exposure measures in the first two trimesters and repeated anthropometry measures ~3 years later as children progress through puberty. There were consistent positive associations between T1 metabolites of the low-molecular weight parent phthalate, DBP (MBP and MIBP), with adiposity among girls. The prenatal association is similar to the results from a cohort of Mexican American children which found an increased odds for overweight and obesity at age 12 years with a doubling in prenatal DBP, though that association was only observed among boys (8). A study conducted by Deierlein et al. found that the sum of low molecular weight phthalates measured at ages 6–8 years was positively associated with repeat measures of BMI and waist circumference several years later among American girls (33). Collectively, these studies point to the importance of timing of outcome and exposure to DBP on adiposity. The importance of timing was previously demonstrated for repeat measures of phthalates through age 8 years and body fat at 8 years in the Health Outcomes and Measures of the Environment (HOME) study. The HOME study reported different directions of associations for some phthalates with body fat in the same children based on whether exposure was assessed in pregnancy, early, or mid-childhood (9).

Among girls, the high molecular weight phthalate metabolite MBzP (T2) was associated with decreased adiposity. A similar relationship was reported for gestational MBzP and decreased body fat at 8 years of age among all children of the HOME study that was near significant (9). However, in the ELEMENT cohort T2 MBzP was associated with increased adiposity measures among boys yet decreased adiposity if the exposure occurred in childhood. These results show the importance of stratifying by sex when assessing the effects of phthalates and of considering multiple exposures during development. While the ELEMENT study along with others gives evidence for

| TABLE 8 | Sample size requirement for significant Sobel test result given varying strengths of effect in a longitudinal model adjusted for covariates. |
|-----------------|-----------------|-----------------|-----------------|
| **Magnitude of standardized effect estimate of mediator on outcome, adjusted for exposure and covariates** | **Weak (0.10)** | **Medium (0.15)** | **Strong (0.20)** |
| **Magnitude of standardized effect of exposure on mediator, adjusted for covariates** | Weak (0.04) | 873 | 819 | 802 |
| | Medium (0.10) | 222 | 167 | 150 |
| | Strong (0.29) | 121 | 61 | 43 |

paths via the Sobel test with strong effect sizes, but lacked the statistical power to detect significant associations with small or medium effect sizes. Thus, while there were no statistically significant Sobel tests, there were several notable findings (Sobel test $p \leq 0.10$) which we will discuss as areas for future study.

In girls, the Sobel test for non-zero mediation neared significance for $H19$ CpG sites 1 and 4 in the association between T3 MBzP and skinfold thickness ($p = 0.07$ and 0.06, respectively); there was also evidence for $H19$ site 4 mediating the relationship with MBzP and BMI-for-age z-score ($p = 0.09$).

Figure 1 illustrates this potential attenuating relationship by which MBzP exposure increases $H19$ DNA methylation which is in turn associated with increased adiposity. However, the direct effect of MBzP on adiposity is negative. In sum, T3 MBzP is inversely associated with skinfold thickness through the direct pathway and is positively associated with skinfold thickness through the mediation pathway with the result of an overall attenuating effect of $H19$ methylation on the inverse relationship between MBzP and skinfold thickness. Instances in which the direct and indirect effects have differing directions of association have previously been described as “inconsistent mediation” (32), and may reflect situations where the mediator, in this case DNA methylation, is protecting against the effect of the exposure.

Among girls, an example of mediation in the expected direction (e.g., the exposure is working through the mediator to influence an outcome), can be seen with $H19$ methylation at CpG sites 1 and 4 in the relationship between T2 MiBP and adiposity outcomes. In all cases, including DNA methylation in the model attenuates the direct effect of T2 MiBP on adiposity by at least 30%, though the Sobel tests for non-zero mediation are not significant ($p$-values 0.11 to 0.39).

In boys, no statistical tests for non-zero mediation reached significance ($Sobel p > 0.1$). Though similar to the girls analysis, there were mediating pairs that displayed estimates indicative of classic mediation (e.g., MBzP from PA visit 1 with $HSD11B2$ CpG #2 on skinfold thickness and waist circumference) that merit further study in a larger H sample size.
the relationship between phthalate exposures in pregnancy or childhood and adiposity, inconsistencies exist across studies (5, 8, 9, 12, 33–35). Inconsistencies may be due to differences in timing of exposure and outcome assessments (e.g., pre-puberty vs. post-puberty), statistical analysis methods (e.g., individual vs. summed phthalates, sex-stratified vs. all children), and population including underlying susceptibility factors (e.g., genetics, epigenetics, other confounders).

Biological mechanisms such as epigenetic alteration may underlie susceptibility to effects on adiposity from phthalate exposures at key developmental windows. While evidence exists for the influence of phthalates, especially gestational exposure, on the epigenome (20–22, 36), this is the first study to examine DNA methylation as a mediator between exposure and adiposity. The H19 imprint control region (ICR) and promoter of HSD11B2 were interrogated due to the functions of these genes in growth regulation as well as previous associations in the ELEMENT cohort between phthalate exposures and DNA methylation at these genes (20). We previously examined relationships between PA visit 1 DNA methylation at four candidate regions and T3 or PA visit 1 exposure biomarkers for phthalates, bisphenol A and lead. Among all children, we reported increased H19 methylation with T3 MIBP and MBzP and increased HSD11B2 methylation with concurrent MEHP (20). Of note in the new analyses reported here that include additional exposure measures in T1 and T2, the association between MIBP and H19 methylation appears to be stronger when the exposure is assessed in T1 among girls (Supplemental Table 1). First trimester is a vulnerable period since the epigenome is reprogrammed in early gestation, and changes from environmental perturbation at this time can be propagated across germ layers (37). In a sample of 17-year old children from Australia, blood leukocyte DNA methylation at the same H19 ICR was associated with skinfold thickness in a cross-sectional analysis (23). We observed a similar positive association among girls between H19 methylation and repeat measures of skinfold thickness in this study. Among boys, HSD11B2 methylation was inversely related to repeat measures of skinfold thickness, BMI z-score, and waist circumference, though only at the 90% confidence level. The longitudinal analysis of these associations suggests that DNA methylation of growth related genes has a persistent association with adiposity throughout adolescence that is sex-specific.

While several studies have examined mediating relationships between phthalate exposure, DNA methylation, and various health outcomes, previous studies have been cross-sectional, focused on outcomes other than adiposity, and/or focused on outcomes in early life. For example, there was cross-sectional evidence for blood leukocyte DNA methylation at TNF-alpha mediating the relationship between MEHP and asthma among children from three study populations (16). In another study, repetitive element cord blood DNA methylation was not found to be a mediator in the relationship between prenatal phthalate exposures and birth outcomes (38). Our analysis did not reveal any statistically significant mediating pathways from phthalate exposure to DNA methylation to adiposity in boys or girls. However, our sex-stratified analysis was underpowered to detect mediation except in the case of large effect sizes (Table 8), and environmentally-induced epigenetic changes are typically small (39). Though not statistically significant, results from the mediation analysis suggest that DNA methylation could serve as a mediator of toxicant effects in some instances or as a protective mechanism influencing susceptibility to effects in other cases. For example, when controlling for H19 methylation, the association of T1 or T2 MIBP with adiposity outcomes among girls are attenuated, and there is a positive indirect effect on adiposity through this potential mediator. On the other hand, controlling for H19 methylation revealed a stronger direct association between T3 MBzP and skinfold thickness and BMI z-score among girls (Sobel p-values 0.06 and 0.09). These two examples present a framework for future research examining epigenetic mediation of exposure-outcome relationships that should consider not only classical mediation (i.e., exposure working through the mediator) but also consider epigenetics as a buffer that reduces the total effect from exposures.

Strengths of this study include the longitudinal design with outcome measurements at two times in peri-adolescence as well as three exposure measures during pregnancy allowing assessment of different windows of vulnerability during pre- and post-natal development. Additionally, including multiple outcome measures allowed for a validity assessment of adiposity,
with directions of association remaining fairly constant across each adiposity proxy. The selection of genes was hypothesis driven based on gene function and previously reported associations with exposure. While a strength, this was also a limitation since additional genes that influence growth and adiposity may be environmentally-responsive and were not examined here. Validity of spot urine concentrations as measures of average exposure is limited due to the short biological half-life of phthalates (40). However, because exposure to phthalates often come from ubiquitous and/or chronic sources, exposure levels are thought to be relatively stable (41). Blood leukocyte DNA represents a variety of cell types, yet we cannot adjust for the cell type proportions as a differential was not obtained at the time of blood sample collection. Statistical power in this study is limited for detecting low to medium mediation effect sizes due to the stratified sample size. Thus, mediation by \( H19 \) and \( HSD11B2 \) methylation, or other genes not included here, should be explored in future studies on phthalates’ effects. Further, due to limited statistical power, our analysis did not test for interactions between exposures and mediators. With the modeling strategy we used, the direct effect is equivalent to a controlled direct effect in the absence of exposure-mediator interaction. If such an interaction exists, the controlled direct effect would need to be computed based on varying levels of the mediator.

In summary, timing and sex-specific associations between phthalates and measures of adiposity in Mexican children assessed twice between ages 8 and 17 years were observed. DNA methylation at growth-regulating genes was also associated with exposures and outcomes. While our mediation analysis was underpowered, epigenetic regulation of these and other related genes may represent avenues by which exposures can exert their effects or by which children can be protected from effects. Since epigenetic profiles vary by race/ethnicity, sex, and age, it is important for future research to consider epigenetics as a susceptibility factor influencing exposure-outcome relationships.

ETHICS STATEMENT

Mothers received detailed information of study procedures and signed a letter of informed consent at initial recruitment and at follow up in accordance with the Declaration of Helsinki. Children provided assent in written or verbal forms when age-appropriate for follow-up visits. Research protocols were approved by the Ethics and Research Committees of participating institutions in Mexico and the USA including at the University of Michigan.

AUTHOR CONTRIBUTIONS

AB, KP, JG, DD, MT-R, and JM contributed to conception and design of the study. AB performed the statistical analysis and wrote the first draft of the manuscript. JG provided oversight in the analysis and writing processes. MT-R, AM-G, KP, DD, JM, BS, and JG were responsible for obtaining data from the cohort and following the cohort. All authors contributed to the manuscript and approved the submission.

FUNDING

This work was supported by U.S. Environmental Protection Agency (US EPA) grants RD834800 and RD83543601 and National Institute for Environmental Health Sciences (NIEHS) grants P20 ES018171, P01 ES02284401, R01 ES007821, R01 ES014930, R01 ES013744, and P30 ES017885. This study was also supported and partially funded by the National Institute of Public Health/Ministry of Health of Mexico. The contents of this publication are solely the responsibility of the grantee and do not necessarily represent the official views of the US EPA or the NIH. Further, the US EPA does not endorse the purchase of any commercial products or services mentioned in the publication.

ACKNOWLEDGMENTS

The authors acknowledge the research staff at participating hospitals and the American British Cowdray Hospital in Mexico City for providing research facilities. We thank the mothers and children for participating in the study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2019.00162/full#supplementary-material

REFERENCES

1. Katsikantami I, Sifakis S, Tzatzarakis MN, Vakomaki E, Kalantzi OI, Tzatsakis AM, et al. A global assessment of phthalates burden and related links to health effects. Environ Int. (2016) 97:212–36. doi: 10.1016/j.envint.2016.09.013

2. Kobrosly BW, Evans S, Miodovnik A, Barrett ES, Thurston SW, Calafat AM, et al. Prenatal phthalate exposures and neurobehavioral development scores in boys and girls at 6–10 years of age. Environ Health Perspect. (2014) 122:521–8. doi: 10.1289/ehp.1307063

3. Teller-Rojas MM, Cantoral A, Cantonwine DE, Schnaas L, Peterson K, Hu H, et al. Prenatal urinary phthalate metabolites levels and neurodevelopment in children at two and three years of age. Sci Total Environ. (2013) 461–2:386–90. doi: 10.1016/j.scitotenv.2013.05.021

4. Meeker JD. Exposure to environmental endocrine disruptors and child development. Arch Pediatr Adolesc Med. (2012) 166:E1–7. doi: 10.1001/archpediatrics.2012.241

5. Braun JM. Early-life exposure to EDCs: role in childhood obesity and neurodevelopment. Nat Rev Endocrinol. (2017) 13:161–73. doi: 10.1038/nrendo.2016.186

6. Vafeiadi M, Myridakis A, Roumeliotaki T, Margetaki K, Chalkiadaki G, Dermitzaki E, et al. Association of early-life exposure to phthalates with obesity and cardiometabolic traits in childhood: sex specific associations. Front Public Health. (2018) 6:327. doi: 10.3389/fpubh.2018.00327

7. Reinehr T. Long-term effects of adolescent obesity: time to act. Nat Rev Endocrinol. (2017) 14:183–8. doi: 10.1038/nrendo.2017.147

8. Harley KG, Berger K, Rauch S, Kogut K, Claus Henn B, Calafat AM, et al. Association of prenatal urinary phthalate metabolite concentrations and childhood BMI and obesity. Pediatr Res. (2017) 82:405–15. doi: 10.1038/pr.2017.112

June 2019 | Volume 7 | Article 162
9. Shaoff J, Papandonatos GD, Calafat AM, Ye X, Chen A, Lanphear BP, et al. Early-life phthalate exposure and adiposity at 8 years of age. *Environ Health Perspect* (2017) 125:9708–8. doi: 10.1289/EHP1022

10. Yang TC, Peterson KE, Meeker JD, Sanchez BN, Zhang Z, Cantoral A, et al. Bisphenol A and phthalates in utero and in childhood: association with child BMI and adiposity. *Environ Res* (2017) 156:326–33. doi: 10.1016/j.envres.2017.03.038

11. Yang TC, Peterson KE, Meeker JD, Sanchez BN, Zhang Z, Cantoral A, et al. Exposure to Bisphenol A and phthalates metabolites in the third trimester of pregnancy and BMI trajectories. *Pediat Obes* (2018) 13:550–7. doi: 10.1111/ijpo.12279

12. Wang H, Zhou Y, Tang C, He Y, Wu J, Chen Y, et al. Urinary phthalate metabolites are associated with body mass index and waist circumference in Chinese school children. *PLoS ONE* (2013) 8:e56800. doi: 10.1371/journal.pone.0056800

13. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. Ppary signaling and metabolism: the good, the bad and the future. *Nat Med* (2013) 19:597–66. doi: 10.1038/nm.3359

14. Ferguson KK, McElrath TF, Chen YH, Mukherjee B, Meeker JD. Urinary phthalate metabolites and biomarkers of oxidative stress in pregnant women: a repeated measures analysis. *Environ Health Perspect* (2015) 123:210–6. doi: 10.1289/ehp.1307996

15. Watkins DJ, Peterson KE, Ferguson KK, Mercado-Garcia A, Tamayo YOM, Cantoral A, et al. Relating phthalate and BPA exposure to metabolism in peripubescence: the role of exposure timing, sex, and puberty. *J Clin Endocrinol Metab* (2016) 101:79–88. doi: 10.1210/jc.2015-2706

16. Wang J, Karmaus WJ, Chen S-L, Holloway JW, Ewart S. Effects of phthalate exposure on asthma may be mediated through alterations in DNA methylation. *Clin Epigenet* (2015) 7:27. doi: 10.1186/s13418-015-0060-x

17. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. *Nat Rev Genet* (2007) 8:253–62. doi: 10.1038/nrg1945

18. Faulk C, Barks A, Liu K, Goodrich JM, Dolinoy DC. Early-life lead exposure results in dose- and sex-specific effects on weight and epigenetic gene regulation in weanling mice. *Epigenomics* (2013) 5:487–500. doi: 10.2217/epi.13.49

19. Sen A, Heredia N, Senut M-C, Hess M, Land S, Qu W, et al. Early life lead exposure causes gender-specific changes in the DNA methylation profile of DNA extracted from dried blood spots. *Epigenomics* (2015) 7:379–93. doi: 10.2217/epi-15.2

20. Goodrich JM, Dolinoy DC, Sanchez BN, Zhang Z, Meeker JD, Mercado-Garcia A, et al. Adolcent epigenetic profiles and environmental exposures from early life through peri-adolescence. *Environ Epigenet* (2016) dvw018:1–11. doi: 10.1093/epip/dvw018

21. Huen K, Calafat AM, Bradman A, Yousef P, Eskenazi B, Holland N. Maternal phthalate exposure during pregnancy is associated with DNA methylation of LINE-1 and Alu repetitive elements in Mexican-American children. *Environ Res* (2016) 148:55–62. doi: 10.1016/j.envres.2016.03.025

22. Tindula G, Murphy SK, Grenier C, Huang Z, Huen K, Escudero-Fung M, et al. DNA methylation of imprinted genes in Mexican–American newborn children with prenatal phthalate exposure. *Epigenomics* (2018) 10:1011–26. doi: 10.2217/epi-2017-0178

23. Huang RC, Galati JC, Burrows S, Bellin LJ, Li X, Pennell CE, et al. DNA methylation of the IGF2/H19 imprinting control region and adiposity distribution in young adults. *Clin Epigenet* (2012) 4:21. doi: 10.1186/1688-7083-4-21

24. Green BB, Armstrong DA, Lesseur C, Paquette AG, Guerin DJ, Kwan LE, et al. The role of placental 11-beta hydroxysteroid dehydrogenase type 1 and type 2 methylation on gene expression and infant birth weight. *Biol Reprod* (2015) 92:149. doi: 10.1095/biolreprod.112.110866

25. Xiao A, Zhao Y, Jin R, Chen J, Wang X, Baccarelli A, et al. Fetal growth restriction and methylation of growth-related genes in the placenta. *Epigenomics* (2015) 8:33–42. doi: 10.2217/epi.15.101

26. Ettinger AS, Lamadrid-Figueroa H, Tellez-Rojo MM, Mercado-Garcia A, Peterson KE, Schwartz JE, et al. Effect of calcium supplementation on blood lead levels in pregnancy: a randomized placebo-controlled trial. *Environ Health Perspect* (2009) 117:26–31. doi: 10.1289/ehp.11886

27. Tellez-Rojo MM, Hernandez-Avila M, Lamadrid-Figueroa H, Smith D, Hernandez-Cadenas L, Mercado A, et al. Impact of bone lead and bone resorption on plasma and whole blood lead levels during pregnancy. *Am J Epidemiol* (2004) 160:668–78. doi: 10.1093/aje/kwh271